Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety of a New 6:2 Influenza Virus Reassortant

NCT01104493 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01104493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01104493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety of a New 6:2 Influenza Virus Reassortant
Lead sponsor
MedImmune LLC
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2010
Completion date
December 31, 2010
Enrollment
300 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy